TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million ...

Granted, Ocrevus Zunovo is a very large volume subcutaneous version of the drug that requires 10 minutes to administer, and the whole process takes about 55 minutes after the first dose ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

A new version called “Ocrevus Zunovo” was recently approved by the Food and Drug Administration and is reportedly much quicker to inject. “Not everybody has the luxury of being able to spend ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...

Dubbed Ocrevus Zunovo, the under-the-skin version of the blockbuster CD20 antibody drug could represent an additional CHF 2 billion sales opportunity, Graham said during the investor call.

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

“In the quarter, the announcement of two highly anticipated partner approvals in the U.S. for Roche’s TECENTRIQ HYBREZA and OCREVUS ZUNOVO reinforces ENHANZE’s track record of 100% phase 3 ...

Over the last 7 days, the United States market has dropped 1.6%, yet it remains up by an impressive 30% over the past year, with earnings forecasted to grow by 15% annually. In this dynamic ...